WELCH DANIEL G 4

What Happened

• Daniel G. Welch, a director of Ultragenyx Pharmaceutical Inc. (RARE), received two equity awards on May 14, 2026: 7,751 restricted stock units (RSUs) and a 14,058-share derivative option award. Both were granted at $0.00 (no cash paid at grant). These are awards (code A) rather than open-market purchases or sales.

Key Details

• Transaction date: May 14, 2026. Form 4 filed May 18, 2026 (appears timely under the 2-business-day Rule 16b-3/Form 4 requirement).
• Grant terms: 7,751 RSUs (F1) and a 14,058-share option/derivative award (F2); both "shall vest in full" on the earlier of the company’s next Annual Meeting of Stockholders or May 14, 2027.
• Price/acquisition: $0.00 per share at grant (no immediate cash outlay).
• Shares owned after transaction: not specified in the provided filing excerpt.
• Footnotes: F1 describes RSU award and vesting; F2 indicates the second award is an option that vests on the same schedule.

Context

• These awards are grants/compensation, not purchases or sales. They do not represent immediate proceeds or an exercised sale — the economic value depends on Ultragenyx’s share price at vesting and any post-vesting actions (hold, sell, or exercise, if applicable).
• For retail investors: awards are routine director compensation and can dilute shares if exercised or settled in stock; they do not necessarily signal the director is buying or selling based on company outlook.